Paul Richardson, MD, attended the Medical College of St. Bartholomew’s Hospital, University of London, UK before becoming chief resident at the Royal Marsden Hospital in London, UK. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, Boston, MA, he joined the Dana-Farber Cancer Institute in Boston, MA in 1994. Prof. Richardson joined the Jerome Lipper Myeloma Centre in 1991 and was subsequently appointed Clinical Director.
In 2012, Prof. Richardson became the first holder of the R. J. Corman Professorship in Medicine at the Dana-Farber Cancer Institute, recognising his outstanding research contributions to the treatment of multiple myeloma. He is on the advisory board for several organisations and recently had his work honoured when he became a recipient of the prestigious IMF Lifetime Achievement Award in 2017.
Speaking on combination therapy, regimen-related toxicity and stem cell transplantation in myeloma
Prof. Richardson investigates and leads the clinical development of novel drug treatment for multiple myeloma. He was involved in the development of the breakthrough monoclonal antibody therapies elotuzumab and daratumumab. His major work has focused on developing lenalidomide, bortezomib and dexamethasone (RVD) as a treatment for newly diagnosed patients, which is now established as the backbone of therapy. Another research interest of Prof. Richardson’s is chemotherapy and transplantation-related toxicity, including the treatment on veno-occlusive disease (VOD).